Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q3 2025 value amounting to $11.8 million.

  • Agios Pharmaceuticals' Net Cash Flow fell 9300.35% to $11.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$161.0 million, marking a year-over-year decrease of 18501.72%. This contributed to the annual value of -$12.0 million for FY2024, which is 7657.77% up from last year.
  • As of Q3 2025, Agios Pharmaceuticals' Net Cash Flow stood at $11.8 million, which was down 9300.35% from $1.9 million recorded in Q2 2025.
  • Agios Pharmaceuticals' 5-year Net Cash Flow high stood at $1.8 billion for Q1 2021, and its period low was -$918.9 million during Q2 2021.
  • Its 5-year average for Net Cash Flow is -$1.8 million, with a median of $1.9 million in 2025.
  • Over the last 5 years, Agios Pharmaceuticals' Net Cash Flow had its largest YoY gain of 2080712.5% in 2021, and its largest YoY loss of 95560.86% in 2021.
  • Quarter analysis of 5 years shows Agios Pharmaceuticals' Net Cash Flow stood at -$197.1 million in 2021, then soared by 108.53% to $16.8 million in 2022, then skyrocketed by 42.01% to $23.9 million in 2023, then plummeted by 843.48% to -$177.5 million in 2024, then soared by 106.67% to $11.8 million in 2025.
  • Its last three reported values are $11.8 million in Q3 2025, $1.9 million for Q2 2025, and $2.7 million during Q1 2025.